Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.

Original reporting
Published Nov 12, 2026, 1:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVAH
Bullish
high confidence
Mentioned
$AVAH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVAHBullishHigh
01

Why it matters

The earnings beat and guidance lift provide a fresh catalyst that could drive the stock higher in the short term.

02

Market read

The article delivers primary company news with new guidance and analyst upgrade, offering a clear trading opportunity.

03

What to watch

Potential headwinds from Medicaid reimbursement changes could temper growth.

Relevance 7/10Novelty 7/10Timing: today

Background

Aveanna Healthcare reported Q3 2026 results beating estimates and raised its full‑year EBITDA guidance.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Raymond James reiterated a Strong Buy on Aveanna (AVAH) and raised its 2026 EBITDA guidance, setting a $15 price target versus the current $13.09 price.

Expected impact

likely upside as the market prices in the higher EBITDA guidance and $15 target

Evidence & confidence

Analyst upgrade with concrete target and guidance lift provides a clear, time‑sensitive catalyst.

Market effects

Positive guidance may lift other home‑health providers as the sector shows earnings strength.

U.S. healthcare services sector could see modest gains.

Limited to U.S. small‑cap healthcare space.

Counterpoint

The guidance raise may already be priced in, limiting upside.

Key entities

  • Raymond James

    Reiterated Strong Buy and set $15 price target.

  • Aveanna Healthcare Holdings Inc.

    Reported Q3 results and raised guidance.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHighAI 8/10

Aveanna Healthcare shares fall 6% despite third quarter beat

Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.